Table 1 Patients’ characteristics and distribution of clinical parameters according to individual preference, n = 119
Parameter of disease (n, %) | Preference to treatment | |
|---|---|---|
i.v. (n = 102) | oral (n = 17) | |
Median age, in years (range) | 72 (65–87) | 70 (65–77) |
ECOG | ||
0 | 22 (21.6) | 4 (23.5) |
1 | 68 (66.7) | 10 (58.8) |
2 | 12 (11.7) | 3 (17.7) |
FIGO stage at primary diagnosis | ||
I | 2 (2) | 1 (5.9) |
II | 7 (6.9) | 1 (5.9) |
III | 62 (60.8) | 13 (76.5) |
IV | 25 (24.5) | 2 (11.7) |
not documented | 6 (5.9) | - |
Histology | ||
Serous papillary | 59 (57.8) | 13 (76.5) |
Mucinous | 12 (11.7) | 3 (17.7) |
Endometrioid | 8 (7.8) | 1 (5.9) |
Others or NOS | 23 (22.6) | - |
Grading at primary diagnosis | ||
G1 | 2 (2) | - |
G2 | 29 (28.4) | 5 (29.4) |
G3 | 61 (59.8) | 12 (70.6) |
not documented | 10 (9.8) | - |
Type of treatment in the adjuvant situation or last recurrence | ||
Surgical tumordebulking | 100 (98) | 17 (100) |
Chemotherapy | 101 (99) | 17 (100) |
Previous hormonal treatment | 8 (7.8) | 2 (11.8) |
Previous Radiotherapy | 6 (5.9) | 1 (5.9) |
Relapse-free interval after primary platinum based therapy | ||
< 6 months | 21 (20.6) | 4 (23.5) |
6–12 months | 28 (27.5) | 7 (41.2) |
> 12 months | 53 (51.9) | 6 (35.3) |
Type of previous chemotherapy regimens (n = 372) | ||
platinum/taxan based | 182 (56.9) | 22 (44.9) |
anthracyclin | 38 (11.9) | 6 (12.2) |
topotecan | 45 (14) | 9 (18.4) |
taxan | 12 (3.8) | 1 (2.1) |
others | 43 (13.4) | 11 (22.4) |
No. of previous chemotherapies for all median (min. / max.) | 3 (1–8) | |
3 (1–8) | 2 (1–7) | |
Recurrent situation at time of registration | ||
1. Recurrence | 13 (12.7) | 1 (5.9) |
2. Recurrence | 25 (24.5) | 8 (47) |
3. Recurrence | 30 (29.4) | 4 (23.5) |
4. Recurrence | 15 (14.7) | 2 (11.8) |
> 4 Recurrencies | 19 (18.6) | 2 (11.8) |